Early voiding dysfunction associated with prostate brachytherapy

Urologic Oncology

Volumn 6, Issue 1, 2001, Pages 20-23

  Wagner, Theodore T ^a   Nag, Subir ^a   Young, Donn ^b   Bahnson, Robert R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Brachytherapy; Cancer; Morbidity; Prostate

Indexed keywords

COTRIMOXAZOLE; DOXAZOSIN; OXYBUTYNIN; PALLADIUM; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; HUMAN; MALE; MICTURITION DISORDER; MORBIDITY; PATIENT EDUCATION; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; QUESTIONNAIRE; SCORING SYSTEM; TUBE; URINE CATHETER; URINE RETENTION;

EID: 0035216290     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00100-9     Document Type: Article

References (7)

1. Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
2. Treatment-related symptoms during the first year following transperineal 125I prostate implantation
3. Transperineal palladium-103 prostate brachytherapy; Analysis of morbidity and seed migration
4. Transperineal ultrasound-guided implantation of the prostate; morbidity and complications
5. Prostate brachytherapy
6. Short-term morbidity from CT-planned transperineal I-125 prostate implants
7. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy for prostate cancer